Villaris Therapeutics

Villaris Therapeutics is a preclinical biopharmaceutical company focused on developing novel antibody therapies for the treatment of vitiligo. The company is developing a novel humanized anti-IL-15R antibody to target T cell depletion, RM for effective and durable treatment of vitiligo and other tissue-specific autoimmune diseases that also involve these cells.